Skip to main content
SpringerLink
Log in

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Background: Preclinical data suggested that sustained inhibition of the anabolic enzyme, ribonucleotide reductase (RR), by hydroxyurea (HU) may be critical for the anticancer effects of the drug. A phase I trial of continuous infusion HU with concomitant hyperfractionated, accelerated radiation therapy (CHU-CHRT) was initiated to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of HU in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck.

Methods: Patients were required to have histologically-documented and radiographically-staged locally advanced SCC of the hypopharynx (AJC stages II, III or IV), oropharynx (AJC stage IV), or oral cavity (AJC stage IV) not amenable to reasonable surgical resection. Eligible patients had adequate bone marrow, hepatic, and renal function and had to give informed consent. Concomitant, hyperfractionated, accelerated radiation therapy (CHRT) consisted of 1.2 Gy BID (6 hour minimum interfraction interval) on weekdays and 1.2 Gy delivered daily on the weekends to a total tumor dose of 74.4 Gy. Continuous infusion hydroxyurea (CHU) was administered at 0.25–0.375 mg/m2/min as a continuous intravenous infusion daily for 5 days with weekends days off for the duration of the radiation therapy. The dose of HU was increased by 0.125 mg/m2/min between dose levels until DLT was reached in 2/6 patients. If the primary had a complete clinical response and biopsies were negative, planned neck dissections were performed.

Results: Fifteen patients were enrolled and are evaluable. The initial dose level, 0.25 mg/m2/min was tolerated by 3/3 patients. At 0.375 mg/m2/min, 3/6 patients experienced grade 3–4 infections, with one patient having a non-fatal, subendocardial infarction. At 0.313 mg/m2/min, no patient experienced DLT.

Conclusion: The MTD for CHU-CHRT was 0.313 mg/m2/min. The toxicities were primarily mucosal and a phase II study is in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bataini P, Brugere J, Vernier J: Results of radical radiotherapy treatment of carcinoma of the pyriform sinus. Int J Radiat Oncol Biol Phys 8: 1276–1277, 1982

    Google Scholar 

  2. Mendenhall W, Parsons J, Devine J, Cassisi NJ, Million RR: Squamous cell carcinoma of the pyriform sinus treated with surgery and/or radiotherapy. Head Neck 10: 88, 1987

  3. Vandenbrouck C, Eschwege F, De-La-Rochefordiere A, Sicot H, Mamelle G, Le-Rident AM, Bosq J, Domenge C: Squamous cell carcinoma of the pyriform sinus: Retrospective study of 351 cases treated at the Institut Gustave-Roussy. Head & Neck Surg 10: 4–13, 1987

    Google Scholar 

  4. Shah J, Shaha A, Spiro R, Strong E: Carcinoma of the hypopharynx. Am J Surg 132: 439–443, 1976

    Google Scholar 

  5. Perez CA: Tonsillar fossa and faucial arch. In: Principles and Practice of Radiation Oncology, p 1020. Edited by Perez CA, Brady LW. Third edition. Lippincott-Raven Publishers, Philadelphia, 1997

    Google Scholar 

  6. Emami B: Oral cavity. In: Principles and Practice of Radiation Oncology, pp 981–1002. Edited by Perez CA, Brady LW. Third edition. Lippincott-Raven Publishers, Philadelphia, 1997

    Google Scholar 

  7. Clayman GL, Weber RS: Cancer of the hypopharynx and cervical esophagus. In: Cancer of the Head and Neck, pp 423–438. Edited by Myers EN, Suen JY. Third edition. W.B. Saunders, Philadelphia

  8. Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, Chandler R. Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study of 73–03 of the Radiation Therapy Oncology group. Head & Neck Surg 10: 19–30, 1987

    Google Scholar 

  9. Vandenbrouck C, Sancho H, Le-Fur R, Richard JM, Cachin Y: Results of a randomized clinical trial of preoperative irradiation versus postoperative in treatment of tumors of the hypopharynx. Cancer 39: 1445–1449, 1977

    Google Scholar 

  10. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88: 890–899, 1996

    Google Scholar 

  11. Arrigada R, Eschwege F, Cachin Y, Richard JM: The value of combining radiotherapy with surgery in the treatment of hypopharyngeal and laryngeal cancers. Cancer 51: 1819–1825, 1983

    Google Scholar 

  12. Cachin Y, Eschwege F: Combination of radiotherapy and surgery in the treatment of head and neck cancer. Cancer Treat Rev 2: 177–191, 1975

    Google Scholar 

  13. Cummings CW, Fredrickson JM, Harker LA, Krause CJ, Schuller DE: Otolaryngology - Head and Neck Surgery. St Louis: C.V. Mosby, 1986

    Google Scholar 

  14. Hawkins NV: The treatment of glottic carcinoma: An analysis of 800 cases. Laryngoscope 85: 1485–1493, 1975

    Google Scholar 

  15. Jesse RH: The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. Laryngoscope 85: 1424–1429, 1975

    Google Scholar 

  16. Shah JP, Tollefsen HR: Epidermoid carcinoma of the supraglottic larynx: Role of neck dissection in initial surgical treatment. Am J Surg 128: 494–498, 1974

    Google Scholar 

  17. Rossi A, Milinari R, Boracchi P: Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a four-year multicenter randomized study. J Clin Oncol 6: 1401–1410, 1988

    Google Scholar 

  18. Olivari AJ, Glait HM, Guardo A, Califano L, Pradier R: Levamisole in squamous cell carcinoma of the head and neck. Cancer Treat Rep 63: 983–990, 1979

    Google Scholar 

  19. Fazekas JT, Sommer C, Kramer S: Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cell cancers of the oral cavity, oropharynx, supraglottic larynx and hypopharynx: Concluding report of an RTOG randomized trial on 638 patients. Int J Radiat Oncol Biol Phys 6: 533–541, 1980

    Google Scholar 

  20. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD: Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98: 1205–1211, 1988

    Google Scholar 

  21. Giri PG, Shanker, LeBlanc M, Al-Sarraf M, Fu KK Cooper J, Vuong T, Forestiere A, Adams G, Sakr W, Schuller D, Ensley J: Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer. Preliminary results of an intergroup randomized trial. INT 0099, SWOG 8892, RTOG 8817, ECOG 2399. Int J Radiat Oncol Biol Phys 36(Suppl)(abstr): 162, 1996

    Google Scholar 

  22. Datta NR, Choudhry AD, Gupta S: Twice a day vs. once a day radiation therapy in head and neck cancer (abstr). Int J Radiat Oncol Biol Phys 17(Suppl 1): 132–133, 1989

    Google Scholar 

  23. Horiot JC, Le-Fur R, Nguyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, VanDenBogaert W, Danczak S, Bolla M, VanGlabbeke M, DePauw M: Hyperfractionation vs. conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of EORTC cooperative group of radiotherapy. Radiother Oncol 25: 231–241, 1992

    Google Scholar 

  24. Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J: Hyperfractionated photon radiation in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (Preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 13: 41–47, 1987

    Google Scholar 

  25. Pinto LHJ, Canary PCV, Araujo CMM, Bacelar SC, Souhami L: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21: 557–562, 1991

    Google Scholar 

  26. Hall EJ: Radiobiology for the Radiologist. Philadelphia, PA: Lippincott, 1994

    Google Scholar 

  27. Xynos FP, Benjamin I, Sapiente R: Adriamycin and hydroxyurea as radiopotentiators in the treatment of squamous cell carcinoma of the cervix implanted in nude mice: A preliminary report. Gynecol Oncol 9: 170–176, 1980

    Google Scholar 

  28. Sinclair WK: Hydroxyurea: Effect on Chinese hamster cells grown in culture. Cancer Res 27: 297–308, 1967

    Google Scholar 

  29. Sinclair WK: The combined effects of hydroxyurea and x-rays in Chinese hamster cells in vitro. Cancer Res 28: 198–206, 1968

    Google Scholar 

  30. Phillips RA, Tolmach LJ: Repair of potentially lethal damage in x-irradiated He-La cells. Radiat Res 29: 413–432, 1966

    Google Scholar 

  31. Piver MS, Howes AE, Suit HD et al.: Effect of hydroxyurea on the radiation response of C3H mouse mammary tumors. Cancer 29: 407–412, 1972

    Google Scholar 

  32. Creasey WA, Capizzi RL, DeConti RC: Clinical biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea. Cancer Chemother Rep 54: 191–194, 1970

    Google Scholar 

  33. Donehower RC: An overview of the clinical experience with hydroxyurea. Sem Oncol 19: 11–19, 1992

    Google Scholar 

  34. Rosner F, Rubin H, Parise F: Studies on the absorption, distribution and excretion of hydroxyurea. Cancer Chemother Rep 55: 167–173, 1971

    Google Scholar 

  35. Wadler S, Horowitz R, Rao J, Mao X, Schlesinger K, Schwartz E: Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: Effects in wild-type and resistant human colon cancer cells. Cancer Chemother Pharmacol 38: 522– 528, 1996

    Google Scholar 

  36. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, 1988

    Google Scholar 

  37. Hamlet S, Faull J, Klein B, Aref A, Fontanesi J, Stachler R, Shamsa F, Jones L, Simpson M: Mastication and swallowing in patients with postirradiation xerostomia. Int J Radiat Oncol Biol Phys 37: 789–796, 1997

    Google Scholar 

  38. Lazarus C: Effects of radiation therapy and voluntary maneuvers on swallowing function in head and neck cancer patients. Clin Comm Dis 3: 11–20, 1993

    Google Scholar 

  39. Lee DJ: Radiation therapy in carcinoma. In: Complications in Otolaryngology - Head and Neck Surgery, pp 223–225. Edited by Johns ME. Philadelphia: BC Decker, 1986

    Google Scholar 

  40. Logemann J: Manual for the Videoflourographic Study of Swallowing. Austin, TX: ProEd, 1993

    Google Scholar 

  41. Richards GJ, Chambers R: Hydroxyurea: A radiosensitizer in the treatment of neoplasms of the head and neck. Amer J Roentgen 105: 555–565, 1969

    Google Scholar 

  42. Stefani S, Eells RW, Abbate J: Hydroxyurea and radiotherapy in head and neck cancer. Radiology 101: 391–396, 1971

    Google Scholar 

  43. Stehman FB, Bundy BN, Thomas G, Keys HM, d'Ablaing G, Fowler WC, Mortel R, Creasman WT: Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 11: 1523–1528, 1993

    Google Scholar 

  44. Hall EJ, Brown JM, Cavanagh J: Radiosensitivity and the oxygen effect measured at different phases of the mitotic cycle using synchronously dividing cells of the root meristem of Vicia faba. Radiat Res 35: 622–634, 1968

    Google Scholar 

  45. Sinclair WK, Losee KA, Bernstein J: Hydroxyurea: Differential lethal effects on cultured mammalian cells during the cell cycle. Science 150: 1729–1731, 1965

    Google Scholar 

  46. Cress AR, Gerner EW: Hydroxyurea inhibits ODC induction, but not the G1 to S-phase transition. Biochem Biophys Res Commun 87: 297–308, 1979

    Google Scholar 

  47. Wadler S, Horowitz RW, Zhang HY: Depletion of deoxyribonucleotide triphosphates fails to inhibit the expression of the E2F transition state enzyme ribonucleotide reductase. Biochem Pharmacol (in press)

  48. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450–474, 1966

    Google Scholar 

  49. Terasima R, Tolmach L: X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490– 492, 1963

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, NY, USA

    Jonathan J. Beitler, Maria Serrano & Allan Brook

  2. Department of Otolaryngology, Montefiore Medical Center, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, NY, USA

    Jonathan J. Beitler, Richard V. Smith & Tamar Kotz

  3. Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, NY, USA

    Hilda Haynes & Scott Wadler

  4. Department of Head and Neck Surgery, Montefiore Medical Center, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, NY, USA

    Carl E. Silver

  5. Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, NY, USA

    Astrid Quish

Authors
  1. Jonathan J. Beitler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard V. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hilda Haynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carl E. Silver
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Astrid Quish
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamar Kotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Serrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Allan Brook
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Scott Wadler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beitler, J.J., Smith, R.V., Haynes, H. et al. A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Invest New Drugs 16, 161–169 (1998). https://doi.org/10.1023/A:1006102716920

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006102716920

Search

Navigation